Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429104 · ClinicalTrials.gov registry record · Phase 2
Herceptin and GM-CSF for Metastatic Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00429104: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00429104 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429104, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the patient's tumor response rate that this protocol will produce. 2. To determine the 1 year progression-free survival that this protocol will produce. Secondary Objective: 1\. To determine whether antibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism of overcoming Herceptin-resistance by use of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF).
Interventions
- DRUG GM-CSF
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2002-08 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429104
The ClinicalTrials.gov registry entry for NCT00429104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GM-CSF is the first listed.
NCT00429104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429104 about?
NCT00429104 is a clinical study titled "Herceptin and GM-CSF for Metastatic Breast Cancer". Primary Objectives: 1. To determine the patient's tumor response rate that this protocol will produce. 2. To determine the 1 year progression-free survival that this protocol will produce. Secondary Objective: 1\. To determine whether antibody-dependent cell-mediated cytotoxicity (ADCC) is the me...
What is the current status of trial NCT00429104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2002-08. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00429104?
The interventions under investigation include: GM-CSF (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00429104?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.